Insider trading

Period: 120 months Stock: BMY Share of holding: 50% or more × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

14 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

14 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

14 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

14 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
14 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
14 decisions over 120 months Remove this filter
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

14 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
9 May 2025
Hickey Benjamin President, RayzeBio Org. · indirect
Sold at will
$3.70K 97 at 38.01
100%
Sold half or more
3 May 2023
Vessey Rupert EVP & President, Research
Sold at will
$3.38M 50,385 at 67.06
51.3%
Sold half or more
6 Feb 2023
Caforio Giovanni Board Chair and CEO
Sold, plan not stated
$17.92M 240,000 at 74.65
50.4%
Sold half or more
13 Sep 2022
Elkins David V EVP, Chief Financial Officer
Sold, plan not stated 2×
$9.55M 133,951 at 71.30
57.1%
Sold half or more
16 Mar 2022
Vessey Rupert EVP, Research & Early Dev.
Sold, plan not stated 2×
$5.16M 74,559 at 69.25
61.7%
Sold half or more
12 Aug 2021
Elkins David V EVP, Chief Financial Officer
Sold, plan not stated 2×
$6.67M 99,691 at 66.95
58.9%
Sold half or more
30 Jul 2021
Vessey Rupert EVP, Research & Early Dev.
Sold, plan not stated 2×
$10.78M 158,393 at 68.07
81.2%
Sold half or more
19 Nov 2020
Vessey Rupert EVP, Research & Early Dev.
Sold, plan not stated 2×
$3.53M 57,591 at 61.30
55.5%
Sold half or more
17 Aug 2020
Eid Joseph SVP,Head Glob. Medical Affairs
Sold, plan not stated
$340.93K 5,327 at 64.00
67.8%
Sold half or more
15 Jun 2020
Paliwal Dinesh C Director
Bought
$499.98K 9,174 at 54.50
70.9%
First buy on file
2 Mar 2020
Vessey Rupert Pres., Research & Early Dev.
Sold, plan not stated
$5.11M 84,308 at 60.59
63.6%
Sold half or more
31 Jul 2019
Bought
$491.92K 11,000 at 44.72
×28
First buy on file
30 Apr 2018
Paliwal Dinesh C Director
Bought
$249.95K 4,770 at 52.40
146%
First buy on file
2 Aug 2017
Bought
$335.62K 6,000 at 55.94
50.0%
First buy on file
Showing 1–14 of 14.